Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Files An 8-K Submission of Matters to a Vote of Security Holders
ITEM5.07
|
Submission of Matters to a Vote of Security Holders. |
(a) On June27, 2017, the Company held its 2017 Annual Meeting of
Stockholders (the Annual Meeting). Of 43,419,478 shares of common
stock issued and outstanding and eligible to vote as of the
record date of April28, 2017, a quorum of 36,107,731 shares, or
83.16% of the eligible shares, was present in person or
represented by proxy.
(b) The following actions were taken at such meeting:
1. The following nominee was reelected to serve on the Companys
Board of Directors as a Class 1 Director until the Companys 2020
annual meeting of stockholders and until his successor is duly
elected and qualified, based on the following votes:
|
|
Votes For |
Votes Withheld |
Broker Non-Votes |
|||||||||
|
|
30,758,529 | 303,775 | 5,045,427 |
2. The selection of Ernst Young LLP as the Companys independent
registered public accounting firm for the fiscal year ending
December31, 2017 was ratified, based on the following results:
|
|
VotesAgainst |
Abstentions |
BrokerNon-Votes |
|||
| 35,853,071 | 240,887 | 13,773 |
3. Approval, on an advisory basis, of the compensation of the
Companys named executive officers as disclosed in the proxy
statement, based on the following votes:
|
|
VotesAgainst |
Abstentions |
BrokerNon-Votes |
|||||
| 30,868,336 | 165,209 | 28,759 | 5,045,427 |
About Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.